Avidity Biosciences to Participate in Upcoming Investor Conference

Rhea-AI Summary

Avidity Biosciences, Inc. will be participating in the TD Cowen 2nd Annual RNA Therapeutics Summit on July 10. The event will be live webcasted and available for replay on Avidity's website.

SAN DIEGO, June 29, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following conference:

• TD Cowen 2^nd Annual RNA Therapeutics Summit on July 10 at 8:35 a.m. PT/11:35 a.m. ET

A live webcast of the event, up-to-date event details and an archived replay of the webcast, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity

Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

Investor Contact:
Kathleen Gallagher
(858) 401-7900 x550
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-301858642.html

SOURCE Avidity Biosciences, Inc.

FAQ

What conference is Avidity Biosciences participating in?

Avidity Biosciences is participating in the TD Cowen 2nd Annual RNA Therapeutics Summit.

When is the conference taking place?

The conference is scheduled for July 10.

Where can I watch the event?

The event will be live webcasted on Avidity's website.

Will there be a replay of the webcast?

Yes, an archived replay of the webcast will be available on Avidity's website.